Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential

benzinga.com/news/health-care/25/09/47628644/maze-shares-jump-as-investors-bet-big-on-experimental-treatments-potential

Maze Therapeutics, Inc. (NASDAQ:MAZE) on Thursday shared clinical results from the Phase 1 healthy volunteer study of MZE782, an oral small molecule targeting the solute transporter, SLC6A19.
MZE782 has the potential to be a best-in-class therapy for patients with phenylketonuria (PKU),…

This story appeared on benzinga.com, 2025-09-11 18:05:57.
The Entire Business World on a Single Page. Free to Use →